CLINICAL TRIALS PROFILE FOR SOLODYN

All Clinical Trials for SOLODYN

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00473083 ↗	Systemic and Topical Treatments for Rash Secondary to Erlotinib in Lung Cancer	Completed	Hoffmann-La Roche	Phase 2	2009-01-01	The purpose of this trial is to determine if rash caused by erlotinib can be successfully treated and if so to determine the optimal treatment approach. Hypothesis: Hypothesis 1: If the incidence of rash is 50% while on erlotinib, prophylactic monotherapy with minocycline can prevent occurrence in 50% of these patients. Hypothesis 2: Treatment of rash is successful in improving rash by at least one Grade in 80% of patients. Hypothesis 3: In patients with untreated rash, the rash will be self-limiting in 25% of patients, and 65% will be grade 1, 2A, and 2b. Ten percent will be grade 3 requiring treatment with monotherapy intervention.
NCT00473083 ↗	Systemic and Topical Treatments for Rash Secondary to Erlotinib in Lung Cancer	Completed	British Columbia Cancer Agency	Phase 2	2009-01-01	The purpose of this trial is to determine if rash caused by erlotinib can be successfully treated and if so to determine the optimal treatment approach. Hypothesis: Hypothesis 1: If the incidence of rash is 50% while on erlotinib, prophylactic monotherapy with minocycline can prevent occurrence in 50% of these patients. Hypothesis 2: Treatment of rash is successful in improving rash by at least one Grade in 80% of patients. Hypothesis 3: In patients with untreated rash, the rash will be self-limiting in 25% of patients, and 65% will be grade 1, 2A, and 2b. Ten percent will be grade 3 requiring treatment with monotherapy intervention.
NCT01048983 ↗	Reducing Symptom Burden - Non Small Cell Lung Cancer (NSCLC)	Withdrawn	National Cancer Institute (NCI)	Phase 1/Phase 2	1969-12-31	The goal of this clinical research study is to compare armodafinil, bupropion, curcumin, and minocycline when given alone or in combination to learn which is better for controlling symptoms, such as the side effects of chemoradiation, when given to treat lung cancer.
NCT01048983 ↗	Reducing Symptom Burden - Non Small Cell Lung Cancer (NSCLC)	Withdrawn	M.D. Anderson Cancer Center	Phase 1/Phase 2	1969-12-31	The goal of this clinical research study is to compare armodafinil, bupropion, curcumin, and minocycline when given alone or in combination to learn which is better for controlling symptoms, such as the side effects of chemoradiation, when given to treat lung cancer.
NCT01173692 ↗	Minocycline for Reduction of Radiation Therapy Treatment-Related Symptom Burden in Oropharynx Cancer: A Randomized Study.	Completed	National Cancer Institute (NCI)	Phase 2	2010-07-22	The goal of this clinical research study is to learn if minocycline can reduce the symptoms reported by patients with oropharynx cancer, nasopharynx cancer, or unknown primary cancer of head and neck, who receive treatment with radiation therapy.
NCT01173692 ↗	Minocycline for Reduction of Radiation Therapy Treatment-Related Symptom Burden in Oropharynx Cancer: A Randomized Study.	Completed	M.D. Anderson Cancer Center	Phase 2	2010-07-22	The goal of this clinical research study is to learn if minocycline can reduce the symptoms reported by patients with oropharynx cancer, nasopharynx cancer, or unknown primary cancer of head and neck, who receive treatment with radiation therapy.
NCT01206348 ↗	Combination Treatment for Moderate to Severe Acne	Completed	Medicis Global Service Corporation	Phase 4	2010-09-01	To determine if a combination of three currently approved acne products are safe and effective for the treatment of moderate to severe acne

Clinical Trial Conditions for SOLODYN

Condition Name

Condition Name for SOLODYN
Intervention	Trials
Lung Cancer	2
Myeloma	2
Head And Neck Cancer	2
Angelman Syndrome	1

Condition MeSH

Condition MeSH for SOLODYN
Intervention	Trials
Lung Neoplasms	4
Carcinoma, Non-Small-Cell Lung	3
Neoplasms, Plasma Cell	2
Multiple Myeloma	2

Clinical Trial Locations for SOLODYN

Trials by Country

Trials by Country for SOLODYN
Location	Trials
United States	30
Canada	4
Germany	4

Trials by US State

Trials by US State for SOLODYN
Location	Trials
Texas	11
Massachusetts	2
North Carolina	2
Michigan	2
Colorado	1

Clinical Trial Progress for SOLODYN

Clinical Trial Phase

Clinical Trial Phase for SOLODYN
Clinical Trial Phase	Trials
Phase 4	2
Phase 2	12
Phase 1/Phase 2	2

Clinical Trial Status

Clinical Trial Status for SOLODYN
Clinical Trial Phase	Trials
Completed	11
Active, not recruiting	3
Recruiting	2

Clinical Trial Sponsors for SOLODYN

Sponsor Name

Sponsor Name for SOLODYN
Sponsor	Trials
M.D. Anderson Cancer Center	11
National Cancer Institute (NCI)	10
Marco Loggia	1

Sponsor Type

Sponsor Type for SOLODYN
Sponsor	Trials
Other	25
NIH	11
Industry	4